Trastuzumab (Herceptin®; Genentech, South San Francisco, CA), a recombinant humanized anti-erbB2/HER-2 monoclonal antibody (MoAb) used in erbB2-overexpressing breast carcinoma, has been shown to have antiangiogenic properties [9]. Here, ERBB2 is linked to breast carcinoma.